# NeoGenomics Inc. (NEO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $17.38, market value $2.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). NeoGenomics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.9×**. Each dollar of revenue is priced at 2.9×.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -0.3%** (5-yr avg -3.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 43.9%**. NeoGenomics Inc. keeps 43.9% of revenue after the direct cost of what it sells.
- **Operating margin: -8.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -14.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -12.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -5.3%**. Return on all capital, debt included, is -5.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -3.8%**. Each dollar of assets produces -3.8% of profit.

## Growth
- **Revenue growth (1 yr): 10.1%** (3-yr 12.6%/yr, 5-yr 10.4%/yr). Revenue grew 10.1% over the last year, against 10.4% a year compounded over five years.

## Financial health
- **Debt to equity: 0.41**. Debt is 0.41 times equity: a conservative balance sheet.
- **Altman Z-score: 3.68**. A Z-score of 3.68 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. NeoGenomics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover NeoGenomics Inc.; the consensus is buy, with an average price target of $19.72 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 115.6%** (YTD 47.8%, 3-mo 59.4%). The shares are up 115.6% over twelve months including dividends.
- **From 52-week high: -12.0%** (145.8% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 1.07** (volatility 54%). Beta of 1.07 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NEO · Page: https://foliofundamentals.com/stocks/neo

Not investment advice.